Related Experiment Video
Updated: May 19, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and
Marianne Benn1, Gerald F Watts, Anne Tybjaerg-Hansen
1Chief Physician, Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark.
Insights
Familial hypercholesterolemia (FH) affects 1 in 137 people, significantly increasing coronary artery disease risk. Many FH patients remain undiagnosed or undertreated, highlighting a critical public health issue.
Area of Science:
- Cardiovascular Medicine
- Genetics
- Epidemiology
Background:
- Familial hypercholesterolemia (FH) diagnosis relies on clinical criteria including personal/family history of premature cardiovascular disease and hypercholesterolemia, alongside genetic confirmation of low-density lipoprotein receptor (LDLR) or apolipoprotein B (APOB) gene mutations.
- The Dutch Lipid Clinic Network criteria are a standard diagnostic tool for FH.
Purpose of the Study:
- To determine the prevalence of FH in an unselected Danish population.
- To investigate the association between FH and coronary artery disease (CAD).
- To assess the use of cholesterol-lowering medication in individuals with FH.
Main Methods:
- The Copenhagen General Population Study included 69,016 unselected, community-based participants.
- FH was defined using the Dutch Lipid Clinic Network criteria (score > 5).
- Coronary artery disease (CAD) was defined as myocardial infarction or angina pectoris.
Main Results:
- The prevalence of definite/probable FH was 0.73% (1 in 137 individuals).
- Twenty percent of FH participants had a pathogenic LDLR or APOB mutation.
- FH was associated with a significantly elevated risk of CAD (OR 13.2 off medication, OR 10.3 on medication), even when treated.
- Only 48% of FH individuals reported taking cholesterol-lowering medication.
Conclusions:
- The prevalence of FH in the Danish general population is higher than previously estimated.
- A substantial proportion of individuals with FH are undiagnosed or undertreated, leading to a high burden of CAD.
- There is a critical need for improved community and primary care strategies for FH diagnosis and management.
Context:
The diagnosis of familial hypercholesterolemia (FH) can be made using the Dutch Lipid Clinic Network criteria. This employs the personal and family history of premature coronary artery disease and hypercholesterolemia and the presence of a pathogenic mutation in the low-density lipoprotein receptor (LDLR) and apolipoprotein B (APOB) genes.
Objective:
We employed this tool to investigate the prevalence of FH and the associations between FH and coronary artery disease and cholesterol-lowering medication in the Copenhagen General Population Study.
Setting:
The study was of an unselected, community-based population comprising 69,016 participants.
Main Outcome Measures:
FH (definite/probable) was defined as a Dutch Lipid Clinic Network score higher than 5. Coronary artery disease was myocardial infarction or angina pectoris.
Results:
The prevalence of FH was 0.73% (one in 137). Of participants with FH, 20% had an LDLR or APOB mutation. The prevalence of coronary artery disease among FH participants was 33%. Only 48% of subjects with FH admitted to taking cholesterol-lowering medication. The odds ratio for coronary artery disease off cholesterol-lowering medication was 13.2 (10.0-17.4) in definite/probable FH compared with non-FH subjects, after adjusting for age, gender, body mass index, hypertension, metabolic syndrome and diabetes, and smoking. The corresponding adjusted odds ratio for coronary artery disease in FH subjects on cholesterol-lowering medication was 10.3 (7.8-13.8).
Conclusion:
The prevalence of FH appears to be higher than commonly perceived in a general population of white Danish individuals, with at least half of affected subjects not receiving cholesterol-lowering medication. The very high risk of coronary artery disease irrespective of use of medication reflects the extent of underdiagnosis and undertreatment of FH in the community and primary care.
Related Concept Videos
Coronary Artery Disease IV: Preventive Measures
Atherosclerosis III: Management
Cholesterol: Significance and Regulation
Considering cholesterol and...
Coronary Artery Disease I: Introduction
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...